Novartis reported CHF7.21B in Cash and Equivalent for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Alcon AG ALC:SW 1.57B 199M
Amgen AMGN:US $ 11969M 5339M
AstraZeneca AZN:LN 7067M 8500M
Bayer BAYN:GR € 4316M 927M
Biogen BIIB:US $ 1541.8M 200.2M
Bristol Myers Squibb BMY:US $ 13540M 2516M
Eli Lilly And LLY:US $ 3788.2M 568.2M
Fresenius FRE:GR € 2413M 163M
Fresenius Medical Care FME:GR € 1562M 154.04M
Genmab GEN:DC DK 8729M 748M
Gilead Sciences GILD:US $ 6837M 1944M
GlaxoSmithKline GSK:LN 3453M 50M
GRIFOLS GRF:SM € 397.86M 16.88M
Hikma Pharmaceutical HIK:LN 2M 321M
Lonza Group LONN:SW 501M 6M
Merck MRK:GR € 1523M 302M
Novartis NOVN:VX SF 7211M 2094M
Novartis NVS:US $ 7211M 2094M
Orion ORNBV:FH € 156.3M 2.7M
Philips PHIA:NA € 3827M 2824M
Recordati REC:IM € 341.93M 70.06M
Regeneron Pharmaceuticals REGN:US $ 3432.4M 1360.2M